2121·Ç·²

OAÈë¿Ú
±¨¸æµ¥ÅÌÎÊ
ÔÚÏ߿ͷþ
2121·Ç·²¡¤(ÖйúÓÎ)ÌåÓý¹Ù·½ÍøÕ¾
ÐÂÎÅÖÐÐÄ
News Center
AIÊÖÒÕÖØ¹¹ÑªÒºÖ×ÁöÒ½ÁÆ·¶Ê½£º2121·Ç·²ÏîÄ¿ÈëÑ¡2025Äê¶Èº¼ÖÝÊÐÖØµã¿ÆÑÐÍýÏë
Ðû²¼£º2025/07/23

¿ËÈÕ £¬£¬£¬£¬£¬£¬£¬º¼ÖÝÊпÆÑ§ÊÖÒÕ¾ÖÐû²¼¡¶2025Äê¶Èº¼ÖÝÊÐÖØµã¿ÆÑÐÍýÏëÏîÄ¿£¨µÚÒ»Åú£©ÄâÁ¢ÏîÏîÄ¿Çåµ¥¡· £¬£¬£¬£¬£¬£¬£¬²¢ÒÑÍê³É¹«Ê¾¡£ ¡£¡£¡£¡£2121·Ç·²ÆìϺ¼ÖÝ2121·Ç·²Ò½Ñ§Ä¥Á·ÖÐÐÄÓÐÏÞ¹«Ë¾É걨µÄ¡°ÁÙ´²×¨²¡¸¨Öú¾öÒéϵͳÑз¢¼°Ó¦Ó᪡ªÑªÒºÖ×Áö¶àģ̬ÖÇÄܸ¨Öú¾öÒéϵͳÑз¢¼°Ó¦Óá±ÏîÄ¿ÀÖ³ÉÈëÑ¡ £¬£¬£¬£¬£¬£¬£¬±ê¼Ç׏«Ë¾ÔÚѪҺÖ×Áö¾«×¼ÕïÁÆÁìÓòµÄÊýÖÇ»¯Êµ¼ùÔÙ»ñȨÍþÈϿɡ£ ¡£¡£¡£¡£

11.png

º¼ÖÝÊпÆÑ§ÊÖÒÕ¾Ö¹«Ê¾Ò³Ãæ½ØÍ¼


ÁÙ´²Ö®Í´£ºÑªÒºÖ×ÁöÕïÁÆÖØ´óÐÔ¸ß


ѪҺÖ×ÁöµÄÕïÁÆÍ¨³£Éæ¼°¶àÖÖÖØ´óµÄÕï¶ÏÊÖÒÕ £¬£¬£¬£¬£¬£¬£¬¼´MICM×ÛºÏÕï¶Ï £¬£¬£¬£¬£¬£¬£¬Æä°üÀ¨ÐÎ̬ѧ¼°Ï¸°û»¯Ñ§£¨Morphology £¬£¬£¬£¬£¬£¬£¬M£©¡¢ÃâÒßѧ£¨Iummunity £¬£¬£¬£¬£¬£¬£¬I £¬£¬£¬£¬£¬£¬£¬Á÷ʽϸ°ûÃâÒ߯ÊÎöºÍ/»ò²¡ÀíÃâÒß×éÖ¯»¯Ñ§£©¡¢È¾É«ÌåºËÐÍÆÊÎö£¨Cytogenetics £¬£¬£¬£¬£¬£¬£¬C£©¡¢·Ö×ÓÉúÎïѧÊÖÒÕ£¨Molecular £¬£¬£¬£¬£¬£¬£¬M£©¡£ ¡£¡£¡£¡£Í¨¹ý×ÛºÏÒÔÉÏÒªÁìµÄ¸÷×ÔÓÅÊÆ £¬£¬£¬£¬£¬£¬£¬Äܹ»Ô½·¢ÖÜÈ«¡¢×¼È·µØ¶ÔѪҺÖ×Áö¾ÙÐÐÕï¶Ï¡¢·ÖÐÍ¡¢Ô¤ºóÅжÏÒÔ¼°ÁÆÐ§¼à²â £¬£¬£¬£¬£¬£¬£¬´Ó¶ø¸üºÃµØÖ¸µ¼ÁÙ´²ÖÎÁÆ¡£ ¡£¡£¡£¡£

 

ÔÚÔçÆÚÕï¶Ï¡¢Ô¤ºóÕ¹Íû¡¢ÁÆÐ§¼à²âµÈ¶à¸ö»·½Ú £¬£¬£¬£¬£¬£¬£¬ÑªÒºÖ×ÁöµÄÕïÁÆ»¹±£´æ´ó×ÚÁÙ´²Í´µã¡£ ¡£¡£¡£¡£ºÃ±È £¬£¬£¬£¬£¬£¬£¬ÔÚÂýÐÔËèϵ°×Ѫ²¡£ ¡£¡£¡£¡£¨CML£©ÖÐ £¬£¬£¬£¬£¬£¬£¬²¿·ÖʹÓðÐÏòÒ©ÎïºóÈ¡µÃÓÅÒìÁÆÐ§µÄ»¼Õß £¬£¬£¬£¬£¬£¬£¬¿ÉÒÔʵÏÖÍ£Ò©ºóµÄÎÞÖÎÁÆ»º½â £¬£¬£¬£¬£¬£¬£¬¶øÏÖÐÐÁÙ´²Ö¸ÄϺÍÏà¹ØÑо¿ÖÐÅú×¢Ö»ÓÐÔ¼50%µÄ»¼ÕßÄܹ»Í£Ò©ÀÖ³É £¬£¬£¬£¬£¬£¬£¬ÔõÑù¸ü¾«×¼µØÕÒµ½ÊʺÏÍ£Ò©µÄ»¼Õß £¬£¬£¬£¬£¬£¬£¬³ÉΪ¼±Ðè½â¾öµÄÎÊÌâ¡£ ¡£¡£¡£¡£¼±ÐÔËèϵ°×Ѫ²¡£ ¡£¡£¡£¡£¨AML£©»¼ÕßÖÎÁƼƻ®µÄÖÆ¶© £¬£¬£¬£¬£¬£¬£¬Í¨³£ÐèÒª²Î¿¼¶àÖÖ¼ì²âÖ¸±ê £¬£¬£¬£¬£¬£¬£¬Õë¶Ô²î±ðΣº¦µÄ»¼ÕßΪҽÉúÌṩ¿ìËÙ¾öÒéÊý¾ÝÒÀ¾Ý £¬£¬£¬£¬£¬£¬£¬³ÉΪ°ü¹ÜÁÆÐ§µÄ»ù´¡¡£ ¡£¡£¡£¡£

 

Òò´Ë £¬£¬£¬£¬£¬£¬£¬ÎÞÂÛÊǽ«ÖØ´óÕï¶ÏÁ÷³Ì¾ÙÐÐ×Ô¶¯»¯Éý¼¶ÒÔÌáÉýЧÂÊ £¬£¬£¬£¬£¬£¬£¬ÕվɴÓÖØ´óµÄ¶àģ̬Êý¾ÝÖÐÕÒ³öÒªº¦µÄ¾öÒéµã £¬£¬£¬£¬£¬£¬£¬È˹¤ÖÇÄܶ¼Êǽâ¾öÏÖÓÐÁÙ´²ÎÊÌâµÄÒªº¦¡£ ¡£¡£¡£¡£


ÆÆ¾ÖÀûÆ÷£º AI¶àģ̬¾öÒéϵͳµÄÊÖÒÕÆÆ¾Ö


ÃæÁÙÖ×Áö°ÐÏòÖÎÁÆÍ£Ò©ºó¾Ó¸ß²»Ïµĸ´·¢Î£º¦¡¢¼±ÐÔ°×Ѫ²¡×ªË²¼´ÊŵĻƽð¾ÈÖÎʱ¼ä´°ÒÔ¼°¶à·¢ÐÔ¹ÇËèÁö£¨MM£©ÁÆÐ§ÆÀ¹À¶ÔÖØ¸´ÇÖÈëÐԹǴ©µÄ¸ß¶ÈÒÀÀµµÈؽ´ýÍ»ÆÆµÄÁÙ´²Äæ¾³ £¬£¬£¬£¬£¬£¬£¬2121·Ç·²×¤×ãÁÙ´²ÐèÇó £¬£¬£¬£¬£¬£¬£¬¿ªÕ¹¡°ÑªÒºÖ×Áö¶àģ̬ÖÇÄܸ¨Öú¾öÒéϵͳÑз¢¼°Ó¦Óá±ÏîÄ¿¡£ ¡£¡£¡£¡£


¸ÃÏîÄ¿½«ÖÂÁ¦ÓÚÉî¶ÈÕûºÏ°üÀ¨ÕæÊµÌìÏÂÓÃÒ©Êý¾Ý¡¢¶à×éѧ·Ö×Ó·ÖÐÍ¡¢¶¯Ì¬Ó°ÏñѧÐÅÏ¢¼°»¼ÕßÈ«²¡³Ì¹ÜÀí¼Í¼ÔÚÄڵĺ£Á¿¶àά¶ÈÊý¾Ý £¬£¬£¬£¬£¬£¬£¬²¢ÔËÓÃÇ°ÑØÈ˹¤ÖÇÄÜÊÖÒÕ£¨AI£©¾ÙÐÐÖÇÄÜÆÊÎöÓëÉî¶ÈÍÚ¾ò £¬£¬£¬£¬£¬£¬£¬Ö¼ÔÚ¹¹½¨Ò»Ì×Í»ÆÆÐÔµÄÁÙ´²¾öÒéÖ§³Öϵͳ £¬£¬£¬£¬£¬£¬£¬ÎªÕâЩÑÏËàÌôÕ½Ìṩ¾«×¼¡¢¸ßЧÇÒ·ÇÇÖÈëÐÔµÄÁ¢Òì½â¾ö¼Æ»®¡ª¡ª


1. CML¡°Í£Ò©ÖúÊÖ¡±¡ª¡ªÈÃTKIÇå¾²¼õÁ¿³ÉΪ¿ÉÄÜ

°ÐÏòÒ©£¨TKI£©ËäÓÐÓà £¬£¬£¬£¬£¬£¬£¬µ«ºã¾Ã·þÓÃ»á¸ø»¼Õß´øÀ´¸±×÷Óú;­¼Ã¼ç¸º¡£ ¡£¡£¡£¡£Ïà¹ØÑо¿ÏÔʾ £¬£¬£¬£¬£¬£¬£¬Ô¼50%µÖ´ïÉî¶È»º½â£¨DMR£©²¢ÊµÑéÍ£Ò©µÄ»¼Õ߻Ḵ·¢¡¾1¡¿¡£ ¡£¡£¡£¡£±¾ÏîÄ¿½«Í»ÆÆ½öÒÀÀµ·Ö×Ó»º½âʱ³¤µÄ¾ÖÏÞ £¬£¬£¬£¬£¬£¬£¬Á¢ÒìÐÔµØÕûºÏ¹ÇËèͿƬ¡¢¶à²ÎÊýÁ÷ʽ£¨¼à²âÃâÒß״̬ÈçNKϸ°û¡¢ºÄ½ßTϸ°û£©¡¢Ï¸°ûÒò×ӵȡ°ÃâÒß×éѧ¡±Êý¾Ý £¬£¬£¬£¬£¬£¬£¬¹¹½¨AIÕ¹ÍûÄ£×Ó £¬£¬£¬£¬£¬£¬£¬Îª»¼ÕßÊä³ö¸öÐÔ»¯µÄ¡°Í£Ò©/¼õÒ©ÀֳɸÅÂÊ¡±ºÍ¸´·¢Î£º¦ÆÀ¹À £¬£¬£¬£¬£¬£¬£¬ÈÃÇ徲ͣҩ³ÉΪ¿ÉÄÜ¡£ ¡£¡£¡£¡£


2. AML¡°7Ìì¼Æ»®ÍƼöÆ÷¡±¡ª¡ª½ô×¥ÖÎÁÆ»Æ½ð´°¿ÚÆÚ

AMLÏ£ÍûѸÃÍ £¬£¬£¬£¬£¬£¬£¬ÖÎÁÆ´°¿ÚÆÚ¶Ì¡£ ¡£¡£¡£¡£»£»£»£»£»£»£»£»ùÒò¼ì²âµÄÆÚ´ýʱ¼ä³ÉΪÕïÁÆÖÐµÄÆ¿¾±¡£ ¡£¡£¡£¡£±¾ÏîÄ¿½«Ñз¢¹ÇËèͿƬÃë¼¶¶àģ̬ÆÊÎöÊÖÒÕ £¬£¬£¬£¬£¬£¬£¬Ê¹ÓÃAIÖ±½Ó´ÓͿƬͼÏñÖÐʵʱ¶¨Î»ÈçFLT3-ITD¡¢NPM1µÈÒªº¦Çý¶¯Í»±ä £¬£¬£¬£¬£¬£¬£¬ÔÚ»¼Õß¾ÙÐл¯ÁÆ»ò¾ÙÐаÐÏòÓÃÒ©7ÌìÄÚÊä³öÓÐÓÃÐÔ¸ÅÂʺÍ×¥ÊÖÐÔÍ»±äÒ©ÎïÆ¥Å佨Òé¡£ ¡£¡£¡£¡£ºóÐøÔÙÍŽáÁ÷ʽÃâÒß·ÖÐͺͻùÒò²âÐòÊý¾Ý £¬£¬£¬£¬£¬£¬£¬¶¯Ì¬Ð£×¼Î£º¦·Ö²ãºÍÒ©ÎïÆ¥Åä £¬£¬£¬£¬£¬£¬£¬ÏÔÖøËõ¶ÌÖÎÁƿմ°ÆÚ £¬£¬£¬£¬£¬£¬£¬ÌáÉýÉúÑÄÂÊ¡£ ¡£¡£¡£¡£


3.MM¡°ÎÞ´´AI-MRD¼à²â¡±¡ª¡ªÍâÖÜÑªÌæ»»¹ÇËè´©´Ì

ÖØ¸´¹ÇËè´©´ÌÊÇMM»¼Õ߯À¹ÀÁÆÐ§ºÍ¸´·¢µÄÖ÷Ҫʹ¿àȪԴ¡£ ¡£¡£¡£¡£±¾ÏîÄ¿½«¹¹½¨»ùÓÚÍâÖÜѪµÄÖÇÄÜMRDÆÀ¹Àϵͳ £¬£¬£¬£¬£¬£¬£¬Í¨¹ýAIÈÚºÏÍâÖÜѪÁ÷ʽ£¨Ñ­»·½¬Ï¸°û£©¡¢¶¨Á¿M-ÂѰ×ÖÊÆ×¡¢ÓÎÀëÖ×ÁöDNA(ctDNA)µÈ¶àģ̬¶¯Ì¬Êý¾Ý £¬£¬£¬£¬£¬£¬£¬Êä³ö¿ÉÚ¹Ê͵ġ°AI-MRD¸ÅÂÊ·ÖÖµ¡± £¬£¬£¬£¬£¬£¬£¬ÊµÏ֏߯µ¡¢ÎÞ´´¡¢È«¾°µÄ²ÐÁôÁö¸ººÉ¼à²â¡£ ¡£¡£¡£¡£Õâ²»µ«ÄܼõÇỼÕßÍ´¿à £¬£¬£¬£¬£¬£¬£¬¸üÄÜÔçÆÚʶ±ð¸ß¸´·¢Î£º¦ £¬£¬£¬£¬£¬£¬£¬Ö¸µ¼Î¬³ÖÖÎÁƵ÷½â¡£ ¡£¡£¡£¡£



Éç»á¼ÛÖµ£º´Ó¾«×¼Ò½ÁƵ½Íƶ¯ÎÀÉú¾­¼Ãѧ¸ïÃü


ѪҺÖ×Áöºã¾Ãλ¾Ó¶ñÐÔÖ×ÁöÖÂËÀÂÊǰÏß £¬£¬£¬£¬£¬£¬£¬Æä¶ñ»¯¿ì¡¢Ò׸´·¢¡¢ÕïÁÆÓöȸß¡£ ¡£¡£¡£¡£ÒÆÖ²¡¢°ÐÏòÒ©¡¢CAR-TËä°ÑÉúÑÄÏ£ÍûÍùÇ°ÍÆÁËÒ»´ó²½ £¬£¬£¬£¬£¬£¬£¬µ«¶¯éü¼¸Ê®ÍòÒÔÖÂÉϰÙÍòµÄÆÆ·Ñ £¬£¬£¬£¬£¬£¬£¬ÈÃÎÞÊý¼ÒÍ¥¡°¿´µÃ¼ûÏ£Íû £¬£¬£¬£¬£¬£¬£¬¹»²»×ÅÒ©¡±¡£ ¡£¡£¡£¡£


±¾ÏîÄ¿Ñз¢µÄ¶àģ̬AIѪҺÖ×Áö¾öÒéϵͳ £¬£¬£¬£¬£¬£¬£¬¾ÍÊÇΪÁËÍÆ¶¯¼â¶ËÖÎÁÆÆ½¼Û¿É¼°¡£ ¡£¡£¡£¡£Ëü½«°ÑÔ­±¾ÐèÒªÊýСʱµÄÖØ´ó¼ì²âѹËõµ½¡°Ãë¼¶¡± £¬£¬£¬£¬£¬£¬£¬ÈÃÂÄÀúÓÃÒ©Éý¼¶Îª¡°Ç§ÈËǧ·½¡±¡£ ¡£¡£¡£¡£»£»£»£»£»£»£»£»ùÓÚÿλ»¼ÕßÁ¿Éí¶¨ÖÆµÄÔ¤·À¡¢Õï¶Ï¡¢ÖÎÁÆÒ»Ì廯¼Æ»® £¬£¬£¬£¬£¬£¬£¬¼È¾«×¼ÓÖʡǮ £¬£¬£¬£¬£¬£¬£¬ÖÜÈ«Â䵨ºóÔ¤¼Æ¿ÉΪº£ÄÚÒ½±£ºÍ»¼Õß¼ÒÍ¥½ÚÔ¼ÉÏÒÚÔªÖ§³ö £¬£¬£¬£¬£¬£¬£¬Èþ«×¼Ò½ÁÆÕæÕý×ß½øÑ°³£ÀèÃñ¼Ò¡£ ¡£¡£¡£¡£


µ±ÑªÒºÖ×ÁöÓö¼û¶àģ̬AI £¬£¬£¬£¬£¬£¬£¬ÎÒÃÇÕý¼ûÖ¤Ò»³¡ÕïÁÆ·¶Ê½µÄÖØ¹¹£º¸üÔçµÄ¸ÉÔ¤¡¢¸ü×¼µÄ¾öÒé¡¢¸üÇáµÄÍ´¿à¡£ ¡£¡£¡£¡£ÏîÄ¿Ñз¢Àú³ÌÖÐ £¬£¬£¬£¬£¬£¬£¬2121·Ç·²»¹½«ÍŽáÉϺ£½»Í¨´óѧҽѧԺÁ¥ÊôÈð½ðÒ½Ôº¡¢»ªÖпƼ¼´óѧͬ¼ÃҽѧԺÁ¥ÊôЭºÍÒ½Ôº¡¢ÎÂÖÝÒ½¿Æ´óѧÁ¥ÊôµÚÒ»Ò½ÔºµÈ¶à¼ÒÍ·²¿Èý¼×Ò½Ôº £¬£¬£¬£¬£¬£¬£¬¿ªÕ¹Ç°Õ°ÐÔ±ÈÕÕÑо¿ £¬£¬£¬£¬£¬£¬£¬È·±£Ëã·¨¿ÉÚ¹ÊÍ¡¢¿ÉÂ䵨¡£ ¡£¡£¡£¡£



½ô¸ú¡°¿µ½¡Öйú¡±¡°Êý×ÖÖйú¡±¹ú¼ÒÕ½ÂÔ°²ÅÅ £¬£¬£¬£¬£¬£¬£¬2121·Ç·²½«Ãª¶¨¡°Ò½Ñ§Õï¶ÏÖÇÄܽâ¾ö¼Æ»®ÒýÁìÕß¡±µÄÕ½ÂÔ¶¨Î» £¬£¬£¬£¬£¬£¬£¬Ò»Á¬Éî¸ûÒ½ÁÆ¿µ½¡³¡¾° £¬£¬£¬£¬£¬£¬£¬ÒÔ¡°AI+Êý¾Ý¡±ÎªÒýÇæ £¬£¬£¬£¬£¬£¬£¬ÒÔ½¹µã×ÔÑÐÊÖÒÕΪÇý¶¯Á¦ £¬£¬£¬£¬£¬£¬£¬Ò»Ö±ÌáÉýÕïÁƾ«×¼¶È¡¢Á¢Ò쿵½¡¹ÜÀíģʽ £¬£¬£¬£¬£¬£¬£¬ÒýÁ칤ҵÉú̬ÖÇÄÜ»¯Î´À´¡£ ¡£¡£¡£¡£


²Î¿¼ÎÄÏ×£º

1. Saussele S, Richter J, Guilhot J, et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol. 2018;19(6):747-757.


ÍøÕ¾µØÍ¼